Model of the Month | Published:

Venomous but not villainous

Lab Animal volume 43, page 11 (2014) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Snake venom: From fieldwork to the clinic: Recent insights into snake biology, together with new technology allowing high-throughput screening of venom, bring new hope for drug discovery. Bioessays 33, 269–279 (2011).

  2. 2.

    & Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads. Toxicon. 62, 56–74 (2013).

  3. 3.

    & Milestones and future prospects in snake venom research. Toxicon. 62, 1–2 (2013).

  4. 4.

    & From snake venom toxins to therapeutics—cardiovascular examples. Toxicon. 59, 497–506 (2012).

  5. 5.

    , & Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction. Cell Immunol. 284, 129–138 (2013).

  6. 6.

    et al. Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression. BMC Cancer 12, 228 (2012).

  7. 7.

    , & Snake venoms: attractive antimicrobial proteinaceous compounds for therapeutic purposes. Cell Mol. Life Sci. 70, 4645–4658 (2013).

  8. 8.

    et al. Molecular characterization of Lys49 and Asp49 phospholipases A2 from snake venom and their antiviral activities against Dengue virus. Toxins (Basel) 5, 1780–1798 (2013).

Download references

About this article

Publication history




    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing